How Sentry is helping covered entities contend with contract pharmacy exclusions
With more and more drug manufacturers excluding their products from 340B contract pharmacies, covered entities are asking two questions: When does this end? And what should we do about it? At Sentry, we’re asking ourselves, how can we best support our customers in these challenging circumstances?
With drugs like AbbVie’s best-selling Humira, Merck’s Keytruda and diabetic drugs from five different manufacturers, it’s safe to say that the contract pharmacy exclusions are taking an ever-increasing bite out of covered entities’ 340B benefits and curtailing their ability to provide critical safety-net services in their communities. We know this from speaking with thousands of covered entity end-users, stakeholders, and advocates. One customer of ours, a large urban health system, has lost over $70 million in program benefits to date from Sanofi alone. The impact is real and has lasting effects on caring for the most vulnerable.
Read the full report here.